Bayesian Statistics Seminar
North Carolina State University
presents
Dr. Steven Kathman
GlaxoSmithKline
"Bayesian Population Pharmacokinetic/Pharmacodynamic Analysis"
ABSTRACT
Over the past decade pharmacokinetic and pharmacodynamic (PK-PD) modeling has advanced considerably. There is a greater need for scientists in drug development to understand the pharmacokinetic properties of a drug and to relate these to the biological actions caused by the drug. PK-PD modeling can assist in determining which dosing regimens are safe and/or efficacious. There are challenges one must face when attempting to model such data. Usually nonlinear mixed effects models are used, and the data collected may be sparse. This presentation will introduce PK-PD modeling, present some of the challenges faced when performing the modeling, and discuss how Bayesian methods can help with some of the challenges. Examples may include modeling the concentration of a drug in plasma, modeling absolute neutrophil counts after the administration of a chemotherapeutic agent (a safety issue), modeling tumor growth or shrinkage (efficacy), and modeling preclinical mouse data - the concentration of a drug in plasma and in tumor.
Download the slides here
Tuesday, October, 30, 2007
4:00 - 5:00 pm
208 Patterson Hall